Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW02 vs Lucentis in Neovascular Age-Related Macular Degeneration
NCT05297292Phase 3Unknown
- Sponsor
- Mabwell
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MW02 in exudative macular degeneration (4 arms), sponsored by Mabwell. Primary endpoint: Best Corrected Visual Acuity at Week 52. Status: unknown.
02
Drugs
MW02
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT05297292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297292.